Detection and tracking of NY-ESO-1-Specific CD8+ T cells by high-throughput T cell receptor β (TCRB) gene rearrangements sequencing in a peptide-vaccinated patient

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Miyai, Manami ^a   Eikawa, Shingo ^b   Hosoi, Akihiro ^a   Iino, Tamaki ^a   Matsushita, Hirokazu ^a   Isobe, Midori ^c   Uenaka, Akiko ^c   Udono, Heiichiro ^b   Nakajima, Jun ^a   Nakayama, Eiichi ^c   Kakimi, Kazuhiro ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c KAWASAKI UNIVERSITY OF MEDICAL WELFARE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR; NY ESO 1 ANTIGEN; PEPTIDE VACCINE; PROTEIN CDR3; T LYMPHOCYTE RECEPTOR BETA CHAIN; TYROSYLLEUCYLALANYLMETHIONYLPROPYLPHENYLALANYLALANYLTHREONYPROPYLMETHIONYLGLUTAMYLALANYLGLUTAMYLLEUCYLALANYLARGINYLARGINYLSERYLLEUCYLALANINE; UNCLASSIFIED DRUG; CANCER VACCINE; CTAG1B PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; CASE REPORT; CD8+ T LYMPHOCYTE; CDR3 GENE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; EX VIVO STUDY; GENE; GENE FREQUENCY; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TECHNIQUE; IMMUNOREACTIVITY; IN VITRO STUDY; LUNG CANCER; MOLECULAR CLONING; NEXT GENERATION SEQUENCING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); TCRB GENE; VACCINATION; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; INTERFERON GAMMA RELEASE ASSAY; LUNG NEOPLASMS; PROCEDURES; TREATMENT OUTCOME;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; GENE REARRANGEMENT, BETA-CHAIN T-CELL ANTIGEN RECEPTOR; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LUNG NEOPLASMS; MEMBRANE PROTEINS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; TREATMENT OUTCOME; VACCINATION;

EID: 84942916791     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136086     Document Type: Article

References (26)

1. Keilholz U, Martus P, Scheibenbogen C (2006) Immune monitoring of T-cell responses in cancer vaccine development. Clin Cancer Res 12: 2346s-2352s. PMID: 16609057.
2. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, et al. (2009) "MIATA"-minimal information about T cell assays. Immunity 31: 527-528. doi:10.1016/j.immuni.2009.09.007 PMID: 19833080.
3. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, et al. (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96. PMID: 8810254.
4. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, et al. (2002) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25: 97-138. PMID: 12074049.
5. Maino VC, Picker LJ (1998) Identification of functional subsets by flow cytometry: Intracellular detection of cytokine expression. Cytometry 34: 207-215. PMID: 9822306.
6. Manz R, Assenmacher M, Pfluger E, Miltenyi S, Radbruch A (1995) Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix. Proc Natl Acad Sci U S A 92: 1921-1925. PMID: 7892200.
7. Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, et al. (2009) Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114: 4099-4107. doi:10.1182/blood-2009-04-217604PMID: 19706884.
8. Six A, Mariotti-Ferrandiz ME, Chaara W, Magadan S, Pham HP, et al. (2013) The past, present, and future of immune repertoire biology-the rise of next-generation repertoire analysis. Front Immunol 4: 413. doi:10.3389/fimmu.2013.00413 PMID: 24348479.
9. Boyd SD, Marshall EL, Merker JD, Maniar JM, Zhang LN, et al. (2009) Measurement and Clinical Monitoring of Human Lymphocyte Clonality by Massively Parallel V-D-J Pyrosequencing. Science Translational Medicine 1: 12ra23. PMID: 20161664.
10. Wu D, Sherwood A, Fromm JR, Winter SS, Dunsmore KP, et al. (2012) High-Throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic Leukemia. Science Translational Medicine 4: 134ra163.
11. Cha E, Klinger M, Hou Y, Cummings C, Ribas A, et al. (2014) Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med 6: 238ra270.
12. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, et al. (2014) PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124: 2246-2259. doi:10.1172/JCI73639 PMID: 24667641.
13. Robert L, Tsoi J, Wang X, Emerson R, Homet B, et al. (2014) CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res 20: 2424-2432. doi:10.1158/1078-0432.CCR-13-2648 PMID: 24583799.
14. Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, et al. (2011) A phase I study of vaccination with NYESO- 1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int J Cancer 129: 2836-2846. doi:10.1002/ijc.25955 PMID: 21448901.
15. Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, et al. (2013) Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. Int J Cancer 132: 345-354. doi:10.1002/ijc.27682 PMID: 22729530.
16. Desombere I, Meuleman P, Rigole H, Willems A, Irsch J, et al. (2004) The interferon gamma secretion assay: A reliable tool to study interferon gamma production at the single cell level. J Immunol Methods 286: 167-185. PMID: 15087231.
17. Pittet MJ, Zippelius A, Speiser DE, Assenmacher M, Guillaume P, et al. (2001) Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol 166: 7634-7640. PMID: 11390521.
18. Morishima S, Akatsuka Y, Nawa A, Kondo E, Kiyono T, et al. (2007) Identification of an HLA-A24- restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: The combined effects of bortezomib and interferon-γ on the presentation of a cryptic epitope. International Journal of Cancer 120: 594-604.
19. Robins H, Desmarais C, Matthis J, Livingston R, Andriesen J, et al. (2012) Ultra-sensitive detection of rare T cell clones. J Immunol Methods 375: 14-19. doi:10.1016/j.jim.2011.09.001 PMID: 21945395.
20. Carlson CS, Emerson RO, Sherwood AM, Desmarais C, Chung M-W, et al. (2013) Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun 4.
21. Lossius A, Johansen JN, Vartdal F, Robins H, Jurate Saltyte B, et al. (2014) High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells. Eur J Immunol 44: 3439-3452. doi:10.1002/eji.201444662PMID: 25103993.
22. Nakasone H, Tanaka Y, Yamazaki R, Terasako K, Sato M, et al. (2014) Single-cell T-cell receptor-beta analysis of HLA-A∗2402-restricted CMV- pp65-specific cytotoxic T-cells in allogeneic hematopoietic SCT. Bone Marrow Transplant 49: 87-94. doi:10.1038/bmt.2013.122 PMID: 23933763.
23. Freeman JD, Warren RL, Webb JR, Nelson BH, Holt RA (2009) Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. Genome Res 19: 1817-1824. doi:10.1101/gr.092924.109 PMID: 19541912.
24. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, et al. (2005) High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201: 241- 248. PMID: 15657293.
25. Lurquin C, Lethe B, De Plaen E, Corbiere V, Theate I, et al. (2005) Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201: 249-257. PMID: 15657294.
26. Valmori D, Dutoit V, Schnuriger V, Quiquerez AL, Pittet MJ, et al. (2002) Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol 168: 4231-4240. PMID: 11937585.